title: The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
abstract: OBJECTIVE
  Optimal chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial. Therefore, we assessed the efficacy and safety of paclitaxel and carboplatin with or without bevacizumab for treating these patients.
  
  
  METHODS
  We analyzed the outcomes of 21 patients with advanced nonsquamous NSCLC with ILD who received paclitaxel and carboplatin without (paclitaxel-carboplatin group; n = 11) or with bevacizumab (paclitaxel-carboplatin-bevacizumab group; n = 10) between April 2008 and October 2013.
  
  
  RESULTS
  The median progression-free survival time of the paclitaxel-carboplatin-bevacizumab group was 5.3 months (95 % CI 0.4-11.6 months) compared with 4.4 months (95 % CI 0.9-6.3 months) for the paclitaxel-carboplatin group (p = 0.060). Their respective median overall survival times were 16.1 months (range 0.4-34.8 months) and 9.7 months (range 2.6-37.0 months) (p = 0.772) with corresponding overall response rates of 40 and 27 % (p = 0.659), respectively. One patient in the paclitaxel-carboplatin-bevacizumab group experienced chemotherapy-related exacerbation of ILD (0/11 vs. 1/10; p = 0.476).
  
  
  CONCLUSIONS
  The addition of bevacizumab to paclitaxel and carboplatin may provide an effective and safe treatment option for patients with advanced nonsquamous NSCLC with ILD.
authors.affiliation: Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2 Minatojima-minamimachi, Chuo-ku, Kobe, 650-0047, Japan, ryoko1031@gmail.com.
authors.forename: Ryoko
authors.initials: R
authors.lastname: Shimizu
authors.forename: Daichi
authors.initials: D
authors.lastname: Fujimoto
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kato
authors.forename: Takehiro
authors.initials: T
authors.lastname: Otoshi
authors.forename: Takahisa
authors.initials: T
authors.lastname: Kawamura
authors.forename: Koji
authors.initials: K
authors.lastname: Tamai
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Kazuma
authors.initials: K
authors.lastname: Nagata
authors.forename: Kyoko
authors.initials: K
authors.lastname: Otsuka
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakagawa
authors.forename: Kojiro
authors.initials: K
authors.lastname: Otsuka
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Katakami
authors.forename: Keisuke
authors.initials: K
authors.lastname: Tomii
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000473:pathology*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel